Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Foyou Pharma CoSHSE:601089 -0.12%57 PS Ratio is 2.28 as of Jul. 30, 2026, which is 2% above its 10-year median of 2.23. GuruFocus rates SHSE:601089 with a GF Score™ of 57/100 and a GF Value™ of ¥16.99 (Fairly Valued). The stock has 1 warning sign investors should review. Among 953 Drug Manufacturers companies, Beijing Foyou Pharma Co ranks better than 50.16% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Beijing Foyou Pharma Co's share price is ¥17.06.
Beijing Foyou Pharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥7.49. Hence, Beijing Foyou Pharma Co's PS Ratio for today is 2.28.
Good Sign:
Beijing Foyou Pharma Co Ltd stock PS Ratio (=2.19) is close to 2-year low of 1.99.
The historical rank and industry rank for Beijing Foyou Pharma Co's PS Ratio or its related term are showing as below:
SHSE:601089'
s PS Ratio Range Over the Past 10 Years
Min: 1.83 Med: 2.23 Max: 4.35
Current: 2.27
During the past 8 years, Beijing Foyou Pharma Co's highest PS Ratio was 4.35. The lowest was 1.83. And the median was 2.23.
SHSE:601089's PS Ratio is ranked better than 50.16% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs SHSE:601089: 2.27
During the past 8 years, Beijing Foyou Pharma Co's highest 3-Year average Revenue per Share Growth Rate was 10.30% per year. The lowest was -2.20% per year. And the median was -0.40% per year.
Back to Basics: PS Ratio
Beijing Foyou Pharma Co (SHSE:601089) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Foyou Pharma Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Foyou Pharma Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Foyou Pharma Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Beijing Foyou Pharma Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Beijing Foyou Pharma Co's Share Price of today is ¥17.06. Beijing Foyou Pharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥7.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Beijing Foyou Pharma Co (SHSE:601089) has a PS Ratio of 2.28 as of Jul. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beijing Foyou Pharma Co and its competitors. This is near median its historical median of 2.23. Over the past decade, Beijing Foyou Pharma Co's PS Ratio has ranged from 1.83 to 4.35. According to the industry distribution chart, Beijing Foyou Pharma Co ranks #475 out of 953 companies in the Drug Manufacturers industry, placing it in the top 49.8%.
Is Beijing Foyou Pharma Co's PS Ratio too high?
Beijing Foyou Pharma Co's current PS Ratio of 2.28 is near median its 10-year median of 2.23. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 4.35. The Drug Manufacturers industry median PS Ratio is 2.27. Beijing Foyou Pharma Co's value of 2.28 is 0.4% above this industry median. Based on the distribution chart, Beijing Foyou Pharma Co ranks #475 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beijing Foyou Pharma Co has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Foyou Pharma Co's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Foyou Pharma Co ranks #475 out of 953 companies for PS Ratio. This puts Beijing Foyou Pharma Co in the upper half of its industry. The industry median PS Ratio is 2.27. Beijing Foyou Pharma Co's value of 2.28 is 0.4% above this benchmark. Historically, Beijing Foyou Pharma Co's own PS Ratio has ranged from 1.83 to 4.35 over the past decade. While the company's 10-year median is 2.23 vs. the industry median of 2.27, Beijing Foyou Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.27, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Foyou Pharma Co's current PS Ratio of 2.28 is 0.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beijing Foyou Pharma Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Foyou Pharma Co's current PS Ratio is 2.28, which is near median its own 10-year median of 2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Foyou Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Foyou Pharma Co (SHSE:601089) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.99, compared to a current price of ¥17.06 — trading 0.4% above its estimated fair value. The current PS Ratio is 2.28, which is near median its 10-year median of 2.23 and 0.4% above the Drug Manufacturers industry median of 2.27. Beijing Foyou Pharma Co's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Beijing Foyou Pharma Co (SHSE:601089), the current PS Ratio is 2.28 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Foyou Pharma Co (SHSE:601089) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Foyou Pharma Co stock appears to be overvalued.
The current stock price of ¥17.06 is trading 0.4% above its estimated GF Value™ of ¥16.99.
GuruFocus considers Beijing Foyou Pharma Co to be Fairly Valued.
Key valuation signals for SHSE:601089:
PS Ratio: 2.28 (near median its 10-year median of 2.23)
GF Value™: ¥16.99 vs. price of ¥17.06 (0.4% above fair value)
Industry Position: 0.4% above the Drug Manufacturers median (#475 of 953)
No single metric tells the full story. See the SHSE:601089 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:601089 has been successfully added to your 
